Darunavir Is a Good Third-Line Antiretroviral Agent for HIV Type 1-Infected Patients Failing Second-Line Protease Inhibitor-Based Regimens in South India
Year: 2012
Type: article
Study design: Observational Study
Abstract: Eleven protease mutations have been associated with reduced susceptibility to darunavir. In this study of 87 HIV-1-infected patients experiencing virological failure to second-line regimens containing protease inhibitors boosted with ritonavir (viral load >1,000 HIV RNA copies/ml), we observed a low prevalence (3%) of ≥3 darunavir resistance-associated mutations, indicating that this drug may be a good option for third-line antiretroviral therapy in southern India.
Language: English
Subfield: Infectious Diseases
Field: Medicine
Domain: Health Sciences
Open Access status: green
Awards: G2291331489, G3206931443, A Multi-Site Investigation into the Effect of HIV Clade on Neurocognition, Biomathematical Analysis of Viral Dynamics and Evolution, HIV-1 Drug Resistance in Different Subtypes, Mentoring Translational Research in HIV, Pooled Nucleic Acid Testing to Identify Antiretroviral Treatment Failure in India, UCSD Department of Medicine HIV/AIDS Clinical Trials Unit, Molecular Epidemiology for HIV Prevention for Drug Users and Other Risk Groups , Effects of Host and Viral Aging on Neurocognition, Determinants of HIV Transmission, G9000010537, G9000097571, UCSD Collaborative Clinical Trials Unit, San Diego Center for AIDS Research (SD CFAR), HIV Neurobehavioral Research Center
OpenAlex ID: W2005160929
